Skip to content
Menu

Clinuvel Pharmaceuticals Limited CUVL

Full chart Compare
Set alert

Price alert · CUVL

All alert types
4.62 USD -0.09 (-1.91%)

Regular-session close

4.65 +0.03 +0.65%

After hours · Nov 20, 4:00 PM ET

4.54 Day range 4.70
4.62 52-week range 8.75
YTD
-45.52%
1 year
-34.65%

Fundamental scorecard

12 of 25 checks passed on CUVL’s reported financials

ValueGrowthProfitabilityHealthDividend

12of 25 checks passed

  • Value 2 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 5 of 5
  • Dividend 3 of 5

Statements to Jun 30, 2026.

Value 2 of 5

  • No data:P/E below its own 5-year median P/E 10.1. Not enough data to decide.
  • Passed:P/E under 20 P/E 10.1: an earnings yield of 9.9%.
  • No data:Price to sales below its own 5-year median Price to sales 3.6. Not enough data to decide.
  • No data:Price to book below its own 5-year median Price to book 1.2. Not enough data to decide.
  • Passed:Free cash flow yield above 4% Free cash flow of 11.8M is 5.1% of the market value.

Growth 1 of 5

  • Passed:Revenue grew over the last year Revenue of 64.3M is +5.2% on the year before.
  • No data:Revenue grew more than 5% a year over five years Not enough data to decide.
  • Failed:Earnings per share grew over the last year EPS 0.46 against 0.46 in the year before.
  • No data:Earnings per share grew more than 5% a year over five years Not enough data to decide.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 1 of 5

  • Passed:Profitable over the last year Net income of 23.2M over FY 2026.
  • No data:Profitable in each of the last five fiscal years Not enough data to decide.
  • Failed:Return on equity above 15% Return on equity of 13.4%.
  • Failed:Net margin above its 5-year average Net margin of 36.0% against a 5-year average of 38.3%.
  • Failed:Free cash flow is at least 80% of net income Free cash flow of 11.8M is 51.1% of net income.

Financial health 5 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 197M against short-term liabilities of 13.4M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 197M against long-term liabilities of 2.01M.
  • Passed:Net debt under 40% of equity More cash than debt: 174M of cash against 1.34M of debt.
  • Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 12.9M is 964.0% of debt.
  • Passed:Operating profit covers interest at least 3 times No interest expense reported.

Dividend 3 of 5

  • Passed:Pays a dividend 1.67M paid over FY 2026.
  • Failed:Yield above 1.5% A yield of 0.7% at the current market value.
  • Passed:Pays out under 75% of profit 7.2% of net income is paid out.
  • Passed:Covered by free cash flow 14.1% of free cash flow is paid out.
  • No data:Not cut in the last five fiscal years Not enough data to decide.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What CUVL owns and owes, as of Jun 30, 2026

Short term and long term

Balance sheet · 204M of assets

Debt, equity and cash by year

Now: 173M more cash than debt

Fiscal years. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.